











Ubiquitin

Prof. Gaddy Getz
Broad Institute of MIT and Harva



Genomic

berrations

Genome

BRCA Initiative

Call of Interest

BRCA germline mutations are approximately ten times more prevalent in Israel compared to the general population. This increased prevalence provides a unique opportunity to study BRCA-associated cancers such as breast, ovarian, prostate, endometrial, and pancreatic cancers.

The RTICC (Technion) and the Broad Institute of MIT and Harvard are initiating a research consortium that will unite researchers from both institutions, as well as other partner institutions, combining Israel's unique genetic diversity and patient population with cutting-edge multi-omics and spatial technologies, as well as basic science and engineering (e.g., biology, mathematics, computer science, physics, chemistry).

The collaboration aims to create a shared platform that fosters cooperation, maximizes resources, and addresses critical questions in BRCA-related and homologous recombination (HRD)-related cancers.

BRCA1/2-mutated cancers. By integrating cancer cell biology, multi-omics, basic sciences, Aldriven computational biology, predictive modeling, and advanced delivery platforms, we aim to harness patient-derived data to uncover novel biomarkers and therapeutic targets. Our goal is to revolutionize patient care—from early detection to breakthrough treatments for advanced-stage disease.

OUR MISSION

- •Provide a comprehensive understanding of the landscape of BRCA-mutant and other HRD tumors.
- •Identify key molecular vulnerabilities for precision therapy.
- •Accelerate biomarker discovery to enhance early detection, disease follow-up, and treatment outcomes.

IMPACT


With BRCA-MAP, we aim to empower clinicians worldwide with actionable insights, enabling personalized treatment strategies and improving outcomes for patients with BRCA-associated cancers. This will include the discovery of fundamental biological concepts for this cancer entity, and the development of new diagnostics and therapeutic tools.

This initiative is for the researchers and clinicians affiliated to the Technion, Broad Institute and partner institutions.

Whether you're a researcher from all RTICC disciplines, a clinician, or an industry partner, there are numerous opportunities to collaborate, contribute, and innovate with us.

Join Us in Transforming BRCA Cancer Research!

Fill out the interest form $\sqrt{\ }$



BRCA Cancer

Cell

For any questions, please contact Tal Gelles